Bei Akademie registrieren
UCB, BE0003739530

UCB stock heads toward the Xetra open after October 23 close

Published on 10/26/2026 at 07:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The Brussels-listed biopharmaceutical company develops medicines for neurological and immunological diseases. Its last recorded closing session was on October 23, 2026.

Business and dated market reference

  • UCB develops medicines for neurological and immunological diseases.
  • The last recorded Euronext Brussels session was dated October 23, 2026.
  • The article is dated October 26, 2026.
Schwarzweiß-Reportagefoto einer Wissenschaftlerin bei der Untersuchung einer Petrischale im Labor
UCB S.A. (BE0003739530) dokumentarisch: authentische Schwarzweiß-Reportage einer Wissenschaftlerin bei sorgfältiger Laboranalyse mit Petrischale, Illustration mit AI erstellt.

On October 23, 2026, UCB stock closed at EUR 272.70 on Euronext Brussels. UCB develops medicines for people living with neurological and immunological diseases, according to its investor-relations materials.

Business and market reference

UCB earns revenue from medicines addressing neurological and immunological conditions, including treatments in epilepsy, osteoporosis, and inflammatory diseases, as described by UCB. The company’s investor-relations page was last updated October 21, 2026. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of UCB stock.

Market context: Market report Euro Stoxx 50.

More news and analysis on UCB stock

Disclaimer...
en | BE0003739530 | UCB | boerse | 70411839 | bgmi